ANN ARBOR, Mich., Sept. 21, 2017 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (TSX-V:ZOM) ("Zomedica" or the "Company"), a veterinary
pharmaceutical and health care solutions company, today announced that an amendment to its bylaws has been approved by the
directors, whereby the quorum for the transaction of business at any meeting of the shareholders shall consist of at least two
persons holding or representing by proxy in aggregate not less than one-third (1/3) of the outstanding shares of the Company
entitled to be voted at the meeting. The change to the bylaws is required in order to meet listing requirements of U.S. stock
exchanges.
In connection with the implementation of the aforementioned amendment to Zomedica’s Bylaws, the Amended and
Restated Bylaws of the Company will be filed and be available under the Company’s corporate profile at www.sedar.com. The Amended and Restated Bylaws are effective immediately and will remain in
effect until they are confirmed, confirmed as amended or rejected by shareholders at the next meeting of shareholders.
About Zomedica
With U.S. operations based in Ann Arbor, Michigan, Zomedica is a veterinary pharmaceutical and health care solutions company
creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians.
Zomedica is developing a diversified portfolio to include diagnostics, devices, innovative drugs, and drug-delivery technologies.
With a team comprised of clinical veterinary professionals, it is Zomedica’s mission to give veterinarians the opportunity to lower
costs, increase productivity, and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.
Follow Zomedica
Reader Advisory
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of the release.
Except for statements of historical fact, this news release and presentation contains certain "forward-looking
information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such
as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain
events or conditions "may" or "will" occur. Although we believe that the expectations reflected in the forward-looking information
are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results,
performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole
or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are
made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ
materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the
results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty
as to whether our strategies and business plans will yield the expected benefits; availability and cost of capital; the ability to
identify and develop and achieve commercial success for new products and technologies; the level of expenditures necessary to
maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability
to secure and maintain strategic relationships; risks pertaining to permits and licensing, intellectual property infringement
risks, risks relating to future clinical trials, regulatory approvals, safety and efficacy of our products, the use of our product,
intellectual property protection and the other risk factors disclosed under our profile on SEDAR at www.sedar.com. Readers are cautioned that this list of risk factors should not be construed as
exhaustive.
The forward-looking information contained in this news release and presentation is expressly qualified by this
cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual
results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned
not to place undue reliance on forward-looking information.
Investor Relations Contact
Shameze Rampertab, CPA, CA
srampertab@zomedica.com
+1 647.283.3630
PCG Advisory Group
Kirin Smith, COO
ksmith@pcgadvisory.com
+1 646.863.6519
www.pcgadvisory.com
Media Contact
Andrea Eberle
aeberle@zomedica.com
+1 734.369.2555
